BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 25189159)

  • 1. Large-scale expansion of γδ T cells and peptide-specific cytotoxic T cells using zoledronate for adoptive immunotherapy.
    Yoshikawa T; Takahara M; Tomiyama M; Nieda M; Maekawa R; Nakatsura T
    Int J Oncol; 2014 Nov; 45(5):1847-56. PubMed ID: 25189159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activated human γδ T cells induce peptide-specific CD8+ T-cell responses to tumor-associated self-antigens.
    Altvater B; Pscherer S; Landmeier S; Kailayangiri S; Savoldo B; Juergens H; Rossig C
    Cancer Immunol Immunother; 2012 Mar; 61(3):385-96. PubMed ID: 21928126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generation and purification of CD8+ melan-A-specific cytotoxic T lymphocytes for adoptive transfer in tumor immunotherapy.
    Oelke M; Moehrle U; Chen JL; Behringer D; Cerundolo V; Lindemann A; Mackensen A
    Clin Cancer Res; 2000 May; 6(5):1997-2005. PubMed ID: 10815925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A single bout of dynamic exercise enhances the expansion of MAGE-A4 and PRAME-specific cytotoxic T-cells from healthy adults.
    LaVoy EC; Bollard CM; Hanley PJ; Blaney JW; O'Connor DP; Bosch JA; Simpson RJ
    Exerc Immunol Rev; 2015; 21():144-53. PubMed ID: 25826370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Usefulness of a novel oncofetal antigen, glypican-3, for diagnosis and immunotherapy of hepatocellular carcinoma].
    Nishimura Y; Nakatsura T; Senju S
    Nihon Rinsho Meneki Gakkai Kaishi; 2008 Oct; 31(5):383-91. PubMed ID: 18974622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy.
    Kondo M; Sakuta K; Noguchi A; Ariyoshi N; Sato K; Sato S; Sato K; Hosoi A; Nakajima J; Yoshida Y; Shiraishi K; Nakagawa K; Kakimi K
    Cytotherapy; 2008; 10(8):842-56. PubMed ID: 19016372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma.
    Komori H; Nakatsura T; Senju S; Yoshitake Y; Motomura Y; Ikuta Y; Fukuma D; Yokomine K; Harao M; Beppu T; Matsui M; Torigoe T; Sato N; Baba H; Nishimura Y
    Clin Cancer Res; 2006 May; 12(9):2689-97. PubMed ID: 16675560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expansion of CD8+ cytotoxic T cells in vitro and in vivo using MHC class I tetramers.
    Savage P; Millrain M; Dimakou S; Stebbing J; Dyson J
    Tumour Biol; 2007; 28(2):70-6. PubMed ID: 17264539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Programmed Death-Ligand 1 on Antigen-presenting Cells Facilitates the Induction of Antigen-specific Cytotoxic T Lymphocytes: Application to Adoptive T-Cell Immunotherapy.
    Goto T; Nishida T; Takagi E; Miyao K; Koyama D; Sakemura R; Hanajiri R; Watanabe K; Imahashi N; Terakura S; Murata M; Kiyoi H
    J Immunother; 2016 Oct; 39(8):306-15. PubMed ID: 27548033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mouse homologue of a novel human oncofetal antigen, glypican-3, evokes T-cell-mediated tumor rejection without autoimmune reactions in mice.
    Nakatsura T; Komori H; Kubo T; Yoshitake Y; Senju S; Katagiri T; Furukawa Y; Ogawa M; Nakamura Y; Nishimura Y
    Clin Cancer Res; 2004 Dec; 10(24):8630-40. PubMed ID: 15623647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Programmed death-1 blockade enhances the antitumor effects of peptide vaccine-induced peptide-specific cytotoxic T lymphocytes.
    Sawada Y; Yoshikawa T; Shimomura M; Iwama T; Endo I; Nakatsura T
    Int J Oncol; 2015 Jan; 46(1):28-36. PubMed ID: 25354479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generation of melanoma-specific cytotoxic T lymphocytes for allogeneic immunotherapy.
    Nolte A; Scheffold C; Slotty J; Huenefeld C; Schultze JL; Grabbe S; Berdel WE; Kienast J
    J Immunother; 2003; 26(3):257-69. PubMed ID: 12806279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancing adoptive cancer immunotherapy with Vγ2Vδ2 T cells through pulse zoledronate stimulation.
    Nada MH; Wang H; Workalemahu G; Tanaka Y; Morita CT
    J Immunother Cancer; 2017; 5():9. PubMed ID: 28239463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of antitumor cytotoxic T lymphocytes from the peripheral blood mononuclear cells of cancer patients using HLA-A2-restricted MAGE-3 peptide in vitro.
    Fujie T; Tanaka F; Mori M; Takesako K; Sugimachi K; Akiyoshi T
    Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2425-30. PubMed ID: 9815643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro stimulation and expansion of human tumour-reactive CD8+ cytotoxic T lymphocytes by anti-CD3/CD28/CD137 magnetic beads.
    Teschner D; Wenzel G; Distler E; Schnürer E; Theobald M; Neurauter AA; Schjetne K; Herr W
    Scand J Immunol; 2011 Aug; 74(2):155-64. PubMed ID: 21517928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T Cells Engineered to Express a T-Cell Receptor Specific for Glypican-3 to Recognize and Kill Hepatoma Cells In Vitro and in Mice.
    Dargel C; Bassani-Sternberg M; Hasreiter J; Zani F; Bockmann JH; Thiele F; Bohne F; Wisskirchen K; Wilde S; Sprinzl MF; Schendel DJ; Krackhardt AM; Uckert W; Wohlleber D; Schiemann M; Stemmer K; Heikenwälder M; Busch DH; Richter G; Mann M; Protzer U
    Gastroenterology; 2015 Oct; 149(4):1042-52. PubMed ID: 26052074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Artificial antigen-presenting cells expressing AFP(158-166) peptide and interleukin-15 activate AFP-specific cytotoxic T lymphocytes.
    Sun L; Guo H; Jiang R; Lu L; Liu T; Zhang Z; He X
    Oncotarget; 2016 Apr; 7(14):17579-90. PubMed ID: 27007051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccination with liposome-coupled glypican-3-derived epitope peptide stimulates cytotoxic T lymphocytes and inhibits GPC3-expressing tumor growth in mice.
    Iwama T; Uchida T; Sawada Y; Tsuchiya N; Sugai S; Fujinami N; Shimomura M; Yoshikawa T; Zhang R; Uemura Y; Nakatsura T
    Biochem Biophys Res Commun; 2016 Jan; 469(1):138-143. PubMed ID: 26616051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies.
    Gottschalk S; Edwards OL; Sili U; Huls MH; Goltsova T; Davis AR; Heslop HE; Rooney CM
    Blood; 2003 Mar; 101(5):1905-12. PubMed ID: 12411306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of antiviral cytotoxic T cells by plasmacytoid dendritic cells for adoptive immunotherapy of posttransplant diseases.
    Aspord C; Laurin D; Richard MJ; Vie H; Chaperot L; Plumas J
    Am J Transplant; 2011 Dec; 11(12):2613-26. PubMed ID: 21883919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.